Boston Scientific revenue and financials

BSX · NYSE · USD

$42.40−0.47%−$0.20

Close · October 5, 2026

In the fiscal year ended December 2025, Boston Scientific reported revenue of $20.07B (+19.87% year over year). Net income was $2.89B, a net margin of 14.4%.

Annual revenue · 2025: $20.07B

$9.08B2016
$9.05B2017
$9.82B2018
$10.74B2019
$9.91B2020
$11.89B2021
$12.68B2022
$14.24B2023
$16.75B2024
$20.07B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +19.87%; 2025 vs 2024
Net income growth: +56.66%; 2025 vs 2024
Net margin: 14.4%; 2024: 11.0%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total revenue	20,074	16,747	14,240	12,682	11,888	9,913	10,735	9,823	9,048	9,076
Cost of revenue	6,221	5,257	4,345	3,956	3,711	3,465	3,116	2,813	2,593	2,424
Gross profit	13,854	11,490	9,896	8,727	8,177	6,448	7,620	7,011	6,455	5,962
Selling, general and administrative	6,887	5,984	5,190	4,520	4,359	—	—	—	—	—
Research and development	2,052	1,615	1,414	1,323	1,204	—	—	—	—	—
Operating income	3,613	2,603	2,343	1,649	1,199	-80.0	1,518	1,506	1,285	447
EBIT	3,971	3,002	2,417	2,033	1,824	—	—	—	—	—
EBITDA	5,339	4,271	3,613	3,169	2,917	—	—	—	—	—
Interest expense	349	305	265	470	341	361	473	241	229	233
Pre-tax income	3,385	2,281	1,985	1,141	1,077	—	—	—	—	—
Income tax	493	436	393	443	36.0	2.0	-4,013	-249	828	-170
Net income	2,892	1,846	1,592	698	1,041	-82.0	4,700	1,671	104	347
Net income to common shareholders	2,898	1,853	1,570	642	985	—	—	—	—	—
Basic EPS	1.96	1.26	1.08	0.45	0.69	-0.08	3.38	1.21	0.08	0.26
Diluted EPS	1.94	1.25	1.07	0.45	0.69	-0.08	3.33	1.19	0.08	0.25
Average shares (basic)	1,480	1,472	1,453	1,431	1,422	—	—	—	—	—
Average shares (diluted)	1,495	1,486	1,464	1,440	1,434	1,417	1,411	1,401	1,393	1,377